Type of leukemia-Chronic lymphocytic leukemia (CLL) - Page 2 of 8 Posts on Medivizor
Navigation Menu

Type of leukemia-Chronic lymphocytic leukemia (CLL) Posts on Medivizor

Evaluating the outcomes of venetoclax treatment in patients with chronic lymphocytic leukemia in the real-world setting

Evaluating the outcomes of venetoclax treatment in patients with chronic lymphocytic leukemia in the real-world setting

Posted by on Mar 28, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate whether venetoclax (Venclexta) is effective and well tolerated in patients with chronic lymphocytic leukemia (CLL) in a real-world setting.  This study concluded that venetoclax is safe and effective in the real-world setting in these patients.   Some background...

Read More

Evaluating the impact of stopping early venetoclax treatment in patients with relapsed/refractory chronic lymphocytic leukemia

Evaluating the impact of stopping early venetoclax treatment in patients with relapsed/refractory chronic lymphocytic leukemia

Posted by on Feb 28, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the impact of venetoclax (Venclexta) modification or early treatment ending on the outcomes of patients with relapsed/refractory chronic lymphocytic leukemia (CLL).  This study concluded that venetoclax treatment modification did not impact outcomes but the early ending of...

Read More

Looking for patients with untreated chronic lymphocytic leukemia to trial a treatment combination.

Looking for patients with untreated chronic lymphocytic leukemia to trial a treatment combination.

Posted by on Oct 11, 2020 in Leukemia | 0 comments

In a nutshell This trial is aiming to examine the effectiveness of zanubrutinib (Brukinsa) in combination with rituximab (Rituxan) to treat chronic lymphocytic leukemia (CLL). The main outcome to be measured is the number of patients who achieve the reduction or disappearance of their CLL. This trial is being carried out in Texas, the...

Read More

Blood Cancer Awareness Month: CLL

Blood Cancer Awareness Month: CLL

Posted by on Sep 27, 2020 in Blog, Leukemia | 2 comments

CLL or Chronic Lymphocytic Leukemia results from a mutation in B lymphocytes, a type of white blood cell that develops in the bone marrow. B-cells produce antibodies, an important part of the immune system. CLL can be slow growing, with small slow changes in the blood counts over years or fast growing, where cancerous B-lymphocytes crowd out the bone...

Read More

The impact of a pharmaceutical care program for patients with chronic lymphocytic leukemia treated with ibrutinib

The impact of a pharmaceutical care program for patients with chronic lymphocytic leukemia treated with ibrutinib

Posted by on Jul 5, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the impact of a pharmaceutical care program on the safety and effectiveness of ibrutinib in patients with chronic lymphocytic leukemia. This study concluded that management of ibrutinib treatment by using a pharmaceutical care program results in improved survival and better...

Read More

Long-term outcomes for CAR-T cells treatment for relapsed or unresponsive chronic lymphocytic leukemia

Long-term outcomes for CAR-T cells treatment for relapsed or unresponsive chronic lymphocytic leukemia

Posted by on May 16, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the outcomes of anti-CD19 chimeric antigen receptor T cells in patients with relapsed or refractory (unresponsive) chronic lymphocytic leukemia.  This study concluded that high-dose treatment may be more effective in these patients in the long term.   Some background Chimeric antigen...

Read More

Combining obinutuzumab and chlorambucil in unfit patients with chronic lymphocytic leukemia

Combining obinutuzumab and chlorambucil in unfit patients with chronic lymphocytic leukemia

Posted by on Mar 24, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated the effectiveness of combining obinutuzumab (Gazyva) and chlorambucil (Leukeran) (O-Clb) to treat physically unfit patients with chronic lymphocytic leukemia (CLL). The authors found that O-Clb is a safe and effective initial treatment for unfit patients with low-risk CLL in a real-world setting. Some background...

Read More